Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Shaw

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Blood|November 23, 2011
Constitutively active ezrin increases membrane tension, slows migration, and impedes endothelial transmigration of lymphocytes in vivo in miceYin Liu, Natalya V Belkina, Chung Park, et al.
The Journal of Infectious Diseases|December 4, 2012
Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1Amanda Hurley, Mindy Smith, Tatiana Karpova, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 18, 2002
CD Antigens 2001David Mason, Pascale André, Armand Bensussan, et al.
Blood|May 17, 2002
CD antigens 2002David Mason, Pascale André, Armand Bensussan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 23, 2002
Reference: CD Antigens 2002David Mason, Pascale André, Armand Bensussan, et al.
Chemmedchem|April 15, 2014
The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 1Thien Duc Tran, Florian Wakenhut, Chris Pickford, et al.
Chemmedchem|April 15, 2014
The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 2Florian Wakenhut, Thien Duc Tran, Chris Pickford, et al.
Cancer|December 3, 2020
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a studyGautam Borthakur, Yishai Ofran, Martin S Tallman, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Blood|November 23, 2011
Constitutively active ezrin increases membrane tension, slows migration, and impedes endothelial transmigration of lymphocytes in vivo in miceYin Liu, Natalya V Belkina, Chung Park, et al.
The Journal of Infectious Diseases|December 4, 2012
Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1Amanda Hurley, Mindy Smith, Tatiana Karpova, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 18, 2002
CD Antigens 2001David Mason, Pascale André, Armand Bensussan, et al.
Blood|May 17, 2002
CD antigens 2002David Mason, Pascale André, Armand Bensussan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 23, 2002
Reference: CD Antigens 2002David Mason, Pascale André, Armand Bensussan, et al.
Chemmedchem|April 15, 2014
The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 1Thien Duc Tran, Florian Wakenhut, Chris Pickford, et al.
Chemmedchem|April 15, 2014
The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 2Florian Wakenhut, Thien Duc Tran, Chris Pickford, et al.
Cancer|December 3, 2020
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a studyGautam Borthakur, Yishai Ofran, Martin S Tallman, et al.
Pageof 6